Ozempic Pharmacokinetics (ADME): How Semaglutide Moves Through Your Body

How Semaglutide Works: Mechanism of Action

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that shares 94% amino acid homology with native human GLP-1 but has been engineered to resist enzymatic degradation. The three structural modifications (an Aib substitution at position 8, a C-18 fatty di-acid chain attached via a linker at lysine-26, and an amino acid substitution at position 34) collectively reduce dipeptidyl peptidase-4 (DPP-4) cleavage and promote strong, non-covalent albumin binding 1. These changes extend the molecule's plasma residence time from the native peptide's 2 to 3 minutes to roughly one week.

The drug activates pancreatic beta-cell GLP-1 receptors in a glucose-dependent manner, stimulating insulin secretion and suppressing glucagon release when blood glucose is elevated 2. Beyond the pancreas, GLP-1 receptors in the hypothalamus and brainstem mediate appetite suppression. Gastric emptying is also delayed. In SUSTAIN-7 (N=1,199), semaglutide 1.0 mg once weekly produced 5.5 to 7.3 kg of weight loss and a 1.8% HbA1c reduction over 40 weeks in patients with type 2 diabetes 3. These pharmacodynamic effects are direct consequences of the pharmacokinetic profile described below.

Absorption: From Injection Site to Systemic Circulation

The subcutaneous bioavailability of semaglutide is 89%, according to data from the FDA-approved prescribing information 4. This is notably higher than liraglutide's 55% bioavailability 5. The fatty acid side chain creates a depot effect at the injection site, slowing the rate of entry into the bloodstream.

Peak plasma concentration (Cmax) occurs 1 to 3 days after a single dose. The absorption profile is flat enough that plasma levels remain therapeutic for the full 7-day dosing interval, which eliminates the pronounced peak-trough swings seen with shorter-acting GLP-1 agonists such as exenatide twice daily 6.

Steady-state is reached after 4 to 5 weekly doses, consistent with the roughly 1-week half-life (accumulation ratio of approximately 3 to 4). At steady-state with semaglutide 1.0 mg, the mean Cmax is approximately 67.2 nmol/L and the AUC over the dosing interval is approximately 9,825 nmol·h/L 4. Exposure increases proportionally across the 0.25 to 2.0 mg dose range, simplifying dose titration decisions.

Injection site (abdomen, thigh, or upper arm) does not meaningfully alter exposure, and the drug can be injected without regard to meals 7.

Distribution: Where Semaglutide Goes in the Body

Semaglutide distributes through a relatively small apparent volume of approximately 12.5 L, which suggests the drug largely remains in the vascular and extracellular fluid compartments rather than partitioning deeply into tissues 4. For context, total plasma volume in a 70-kg adult is about 3 L, so 12.5 L indicates moderate extravascular distribution.

Albumin binding exceeds 99%. The C-18 fatty di-acid chain drives this interaction and is the primary reason for the extended half-life 1. By comparison, liraglutide's C-16 fatty acid produces protein binding above 98% and a half-life of only 13 hours 5. The extra two carbons in semaglutide's acyl chain and the di-acid configuration tighten albumin affinity and slow renal clearance.

Because of the strong albumin binding, clinicians should consider conditions that reduce serum albumin (such as nephrotic syndrome, advanced liver cirrhosis, or severe malnutrition) as potential modifiers of free drug concentration, although formal studies in these populations are limited.

Metabolism: How the Body Breaks Down Semaglutide

Semaglutide is metabolized through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid side chain. No single cytochrome P450 enzyme or organ system dominates the metabolic pathway 4. This is a meaningful clinical advantage: the absence of CYP-dependent metabolism substantially reduces the risk of drug-drug interactions at the metabolic level.

The FDA pharmacology review identified three primary metabolites in plasma after subcutaneous dosing, all resulting from cleavage of the peptide at different points along the backbone 8. These metabolites retain the fatty acid moiety but lose GLP-1 receptor binding activity, so they are pharmacologically inactive. The intact parent compound accounts for the vast majority of circulating drug-related material.

A formal drug interaction study showed that semaglutide does not inhibit or induce CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 at clinically relevant concentrations 9. This means co-administration with statins, warfarin, oral contraceptives, or other CYP-substrate medications does not require dose adjustment based on metabolic interaction alone.

The delayed gastric emptying caused by semaglutide could theoretically slow the absorption of co-administered oral medications. However, clinical interaction studies with metformin, warfarin, digoxin, and combined oral contraceptives did not show clinically relevant changes in their exposure 9.

Elimination: Clearance and the One-Week Half-Life

Semaglutide's terminal elimination half-life is approximately 1 week (roughly 165 hours). Total clearance is approximately 0.05 L/h 4. The drug is eliminated through both urine and feces in roughly equal proportions. Approximately 3% of an administered dose is excreted as intact semaglutide in urine 8.

This half-life means the drug persists in circulation for roughly 5 weeks after the last dose (five half-lives to reach near-complete elimination). Prescribers and patients should understand this residual exposure window when managing side effects or planning transitions to other therapies.

A population pharmacokinetic analysis of over 1,500 subjects from the SUSTAIN clinical program found that body weight is the most significant covariate affecting semaglutide exposure 10. Higher body weight increases the volume of distribution and clearance modestly, but the magnitude does not warrant weight-based dose adjustment per FDA labeling. Age, sex, race, and ethnicity did not produce clinically meaningful differences in exposure 10.

Renal and Hepatic Impairment: Does Organ Function Change Exposure?

Semaglutide's proteolytic metabolism makes it relatively insensitive to single-organ impairment. A dedicated renal impairment study (including subjects on dialysis) showed no clinically relevant change in semaglutide exposure across mild, moderate, severe, and end-stage renal disease categories 11. No dose adjustment is needed for any degree of renal impairment, according to the Kidney Disease: Improving Global Outcomes (KDIGO) and the FDA label 12.

A hepatic impairment study covering Child-Pugh A, B, and C categories similarly showed no clinically significant changes in semaglutide pharmacokinetics 13. AUC and Cmax values in subjects with hepatic impairment fell within the range observed in healthy volunteers. No dose adjustment is recommended, though clinical monitoring remains prudent in decompensated cirrhosis given the limited real-world data in that population.

These findings contrast with some older GLP-1 receptor agonists. Exenatide, for example, carries a contraindication for severe renal impairment (eGFR <30 mL/min) because of renal-dependent clearance 14.

Comparing Semaglutide Pharmacokinetics to Other GLP-1 Agonists

The pharmacokinetic properties of semaglutide differ meaningfully from other agents in the GLP-1 receptor agonist class. Liraglutide (Victoza/Saxenda) has a half-life of 13 hours, requiring daily dosing and producing higher peak-to-trough fluctuations 5. Dulaglutide (Trulicity) achieves once-weekly dosing through a fusion protein strategy (linking the GLP-1 analogue to an IgG4 Fc fragment), producing a half-life of approximately 5 days and a Tmax of 24 to 72 hours 15.

Semaglutide's 89% subcutaneous bioavailability is the highest in the class. Tirzepatide (Mounjaro), a dual GIP/GLP-1 agonist, has a comparable half-life of approximately 5 days and achieves once-weekly dosing through a similar fatty acid acylation strategy 16.

The oral formulation of semaglutide (Rybelsus) uses a sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) absorption enhancer but achieves only 0.4 to 1% oral bioavailability, meaning the 14-mg oral tablet delivers a systemic exposure roughly equivalent to the 0.5-mg subcutaneous injection 17. This low bioavailability requires fasting conditions (at least 30 minutes before any food, beverage, or other oral medication with no more than 4 oz of plain water) for consistent absorption.

Clinical Relevance of Pharmacokinetic Properties

Three pharmacokinetic features have direct clinical implications. First, the extended half-life and flat concentration profile mean that missing a dose by 1 to 2 days does not produce a clinically significant drop in drug levels. The FDA label permits administration up to 5 days after the scheduled day before requiring a skipped-week reset 4.

Second, the slow clearance means GI side effects (nausea, vomiting, diarrhea) that occur during dose escalation may persist for weeks after dose reduction or discontinuation. The SUSTAIN-1 trial (N=388) reported nausea in 20.3% of patients on semaglutide 1.0 mg, with most episodes occurring during the first 8 to 12 weeks 18. Setting expectations around this timeline is essential.

Third, the dose-proportional kinetics across 0.25 to 2.0 mg simplify the dose-response relationship. Clinicians can predict that doubling the dose will approximately double the AUC, making titration decisions straightforward. The 4-week escalation intervals recommended in the label align with the time to reach a new steady-state after each dose change 4.

The American Diabetes Association's 2024 Standards of Care recognize GLP-1 receptor agonists with proven cardiovascular benefit (including semaglutide, based on SUSTAIN-6 data showing a 26% reduction in major adverse cardiovascular events) as preferred second-line agents after metformin in patients with established atherosclerotic cardiovascular disease 19.